The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Investigation of predictive biomarkers for R1507, an anti-IGF1R antibody, in patients with advanced non-small cell lung cancer with progression after first-line chemotherapy.
K. Habben
No relevant relationships to disclose
P. Delmar
No relevant relationships to disclose
C. M. Brownstein
No relevant relationships to disclose
W. Koehler
No relevant relationships to disclose
K. Kuenkele
No relevant relationships to disclose
O. Splesis
No relevant relationships to disclose
S. S. Ramalingam
Consultant or Advisory Role - Astellas Pharma; Genentech; OSI Pharmaceuticals
Honoraria - Genentech
J. A. Engelman
Consultant or Advisory Role - Genentech
D. Chen
No relevant relationships to disclose